-
1Academic Journal
Συγγραφείς: I. B. Medvedev, E. V. Samodurova, S. V. Svetlichnaya, L. V. Batalina, N. N. Dergacheva, И. Б. Медведев, Е. В. Самодурова, С. В. Светличная, Л. В. Баталина, Н. Н. Дергачёва
Πηγή: Ophthalmology in Russia; Том 20, № 2 (2023); 208-214 ; Офтальмология; Том 20, № 2 (2023); 208-214 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2023-2
Θεματικοί όροι: ИЛ-23, immuno-inflammatory diseases, genetically engineered biological drugs, immunosuppressants, corticosteroids, biological modulators of the immune response, tumor necrosis factor-α, IL-6, IL-17, IL-23, иммуновоспалительные заболевания, генно-инженерные биологические препараты, иммуносупрессанты, кортикостероиды, биологические модуляторы иммунного ответа, фактор некроза опухоли-α, ИЛ-6, ИЛ-17
Περιγραφή αρχείου: application/pdf
Relation: https://www.ophthalmojournal.com/opht/article/view/2098/1091; Foster CS, Vitale AT. Diagnosis and Treatment of Uveitis. 2nd Edition. New Delhi: Jaypee Brothers Medical Publishers; 2013.; Давыдова ГА, Лисицына ТА, Ковалева ЛА, Сорожкина ЕС, Зайцева АА, Байсангурова АА. Клинические вариации увеитов при иммуновоспалительных заболеваниях. Обзор литературы. Часть 1. Офтальмология. 2022;19(3):465–474. doi:10.18008/1816-5095-2022-3-465-474.; Tsirouki T, Dastiridou A, Symeonidis Ch, Tounakaki O, Brazitikou I, Kalogeropoulos Ch, Androudi S. A Focus on the Epidemiology of Uveitis, Ocular Immunology and Inflammation, 2018;26(1):2 –16. doi:10.1080/09273948.2016.1196713.; Давыдова Г.А., Лисицына Т.А., Ковалева Л.А., Сорожкина Е.С., Зайцева А.А., Байсангурова А.А. Клинические вариации увеитов при иммуновоспалительных заболеваниях. Обзор литературы. Часть 2. Офтальмология. 2022;19(4):719–726. doi:10.18008/1816-5095-2022-4-719-726G.; Арбеньева НС, Чехова ТА, Братко ВИ, Обухова ОО, Горбенко ОМ, Шваюк АП, Повещенко ОВ, Трунов АН, Черных ВВ. Влияние комплексного лечения с использованием тромбоцитарной аутоплазмы на клинико-лабораторные показатели пациентов с эндогенным увеитом и макулярным отеком. Сибирский научный медицинский журнал. 2019;39(5):110–118. doi:10.15372/SSMJ20190513.; Cаlamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Beccet’s disease in the US: a populationbased study. Arthritis Rheum. 2009;61(5):600–604. doi:10.1002/art.24423.; Галушко ЕА, Насонов ЕЛ. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018;46(1):32–39. doi:10.18786/2072-0505-2018-46-1-32-39.; Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509–516. doi:10.1016/j.ajo.2005.03.057.; Denniston A, Barry R, Nguyen Q, Lee R, Murray P. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol. 2014;8:1891–1911. doi:10.2147/opth.s47778.; Garcia-Montoya L, Gul H, Emery P. Recent advances in ankylosing spondylitis: understanding the disease and management. F1000Res. 2018 Sep 21;7:F1000 Faculty Rev-1512. PMID: 30345001; PMCID: PMC6173104. doi:10.12688/f1000research.14956.1.; Hansen IS, Schoonejans JM, Sritharan L, van Burgsteden JA, Ambarus CA, Baeten DLP, den Dunnen J. ER stress abrogates the immunosuppressive effect of IL-10 on human macrophages through inhibition of STAT3 activation. Inflamm Res. 2019 Sep;68(9):775–785. Epub 2019 Jun 21. PMID: 31227842; PMCID: PMC6667425. doi:10.1007/s00011-019-01261-9.; Rademacher J, Poddubnyy D, Pleyer U. Uveitis in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020 Sep 12;12:1759720X20951733. doi:10.1177/1759720X20951733. PMID: 32963592; PMCID: PMC7488890.; Дроздова ЕА. Вопросы классификации и эпидемиологии увеитов. Клиническая офтальмология: РМЖ. 2016;3:155–159. doi:10.21689/2311-7729-2016-16-3-155-159.; Давыдова Г.А., Лисицына Т.А., Ковалева Л.А., Сорожкина Е.С., Зайцева А.А., Байсангурова. А.А. Клинические вариации увеитов при иммуновоспалительных заболеваниях. Обзор литературы. Часть 1. Офтальмология. 2022;19(3):465–474. doi:10.18008/1816-5095-2022-3-465-474.; Cantini F, Nannini C, Cassara E, Kaloudi O, Niccoli L. Uveitis in Spondyloarthritis: An Overview. J Rheumatol Suppl. 2015 Nov;93:27-9. doi:10.3899/jrheum.150630.; Lee JH, Choi M, Rim THT, Lee SC, Lee CS. Clinical Characteristics and Prognostic Factors in Ankylosing Spondylitis Associated Uveitis. Ocul Immunol Inflamm. 2019;27(1):64–69. doi:10.1080/09273948.2017.1359630. Epub 2017 Oct 11. PMID: 29020487.; Balasubramaniam B, Chong YJ, Azzopardi M, Logeswaran A, Denniston AK. Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives. J Inflamm Res. 2022 Nov 28;15:6439–6451. doi:10.2147/JIR.S288294. PMID: 36467992; PMCID: PMC9717596.; Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-Kearney M-L, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Seminars in Arthritis and Rheumatism. 2019;49(3):438–445. SSN 0049-0172. doi:10.1016/j.semarthrit.2019.06.004.; Valdes LM, Sobrin L. Uveitis Therapy: The Corticosteroid Options. Drugs. 2020;80:765–773. doi:10.1007/s40265-020-01314-y.; Арбеньева НС, Чехова ТА, Братко ВИ, Трунов АН, Черных ВВ. Оценка эффективности комплексного лечения неинфекционных увеитов, сопровождающихся макулярным отеком. Современные технологии в офтальмологии. 2018;3:199–202.; Крахмалева ДА, Пивин ЕА, Труфанов СВ, Маложен СА. Современные тенденции в лечении увеитов. Офтальмология. 2017;14(2):113–119. doi:10.18008/1816-5095-2017-2-113-119.; Hunter RH, Lobo A-M. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clinical Ophthalmology. 2011;5:1613–1621.; Лебедев ОИ, Суров АВ, Матненко ТЮ, Салихов ММ. Иммунотерапия увеитов, ассоциированных с системными заболеваниями. РМЖ. Клиническая офтальмология 2013;13(2):69–71.; The Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE. Randomized Comparison of Systemic Anti-inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior and Panuveitis: The Multicenter Uveitis Steroid Treatment Trial. Ophthalmology. 2011 October;118(10):1916–1926. doi:10.1016/j.ophtha.2011.07.027.; Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005 Jul;112(7):1192–1198. doi:10.1016/j.ophtha.2005.03.013.; Tirelli F, Zannin ME, Vittadello F, Agnolucci J, Mazzarolo M, Zulian F. Methotrexate Monotherapy in Juvenile Idiopathic Arthritis Associated Uveitis: Myth or Reality? Ocular Immunology and Inflammation. 2022 Oct-Nov;30(7-8):1763-1767. doi:10.1080/09273948.2021.1951303.; Smith WM. Cyclosporine: A Historical Perspective on Its Role in the Treatment of Noninfectious Uveitis. Journal of Ocular Pharmacology and Therapeutics. 2017;5:247–262. doi:10.1089/jop.2016.0155.; Дроздова ЕА. Иммуносупрессивная терапия неинфекционных увеитов и ретиноваскулитов. Офтальмология. 2012;9(2):58–61. doi:10.18008/1816-5095-2012-2-58-61.; Лисицына ТА, Давыдова ГА, Алекберова ЗС, Голоева РГ, Катаргина ЛА, Насонов ЕЛ. Сравнительная эффективность различных схем иммуносупрессивной терапии увеита у пациентов с болезнью Бехчета. Научно-практическая ревматология. 2021;59(2):173–183. doi:10.47360/1995-4484-2021-173-183.; Duica I, Voinea LM, Mitulescu C, Istrate S, Coman IC, Ciuluvica R. The use of biologic therapies in uveitis. Rom J Ophthalmol. 2018 Apr-Jun;62(2):105–113. PMID: 30206553; PMCID: PMC6117529.; Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R, Dick AD. Long-term efficacy and tolerability of TNFα inhibitors in the treatment of noninfectious ocular inflammation: an 8-year prospective surveillance study. Br J Ophthalmol. 2021 Sep;105(9):1256–1262. doi:10.1136/bjophthalmol-2018-312767. Epub 2019 Mar 12. PMID: 30862619; PMCID: PMC8380906.; Van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, Kok MR, Schilder AM, Verhoef M, van der Horst-Bruinsma IE. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study. J Rheumatol. 2019 Feb;46(2):153–159. doi:10.3899/jrheum.180312. Epub 2018 Nov 1. PMID: 30385705.; Arepalli S, Rosenbaum JT. The use of biologics for uveitis associated with spondyloarthritis. Curr Opin Rheumatol. 2019 Jul;31(4):349–354. doi:10.1097/BOR.0000000000000619. PMID: 31107288.; van der Horst-Bruinsma IE, Robinson PC, Favalli EG, Verbraak FD, Kim M, Kumke T, Bauer L, Hoepken B, Deodhar A. Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review. Rheumatol Ther. 2022 Dec;9(6):1481–1497. doi:10.1007/s40744-022-00486-1. Epub 2022 Sep 30. PMID: 36178585; PMCID: PMC9562975.; Leclercq M, Desbois AC, Domont F, Maalouf G, Touhami S, Cacoub P, Bodaghi B, Saadoun D. Biotherapies in Uveitis. J Clin Med. 2020 Nov 8;9(11):3599. doi:10.3390/jcm9113599. PMID: 33171664; PMCID: PMC7695328.; Mesquida M, Molins B, Llorenc V, Hernandez MV, Espinosa G, Sainz de la Maza M, Adan A. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38(7):1361–1370. doi:10.1097/IAE.0000000000001690.; Maccora I, Abu Rumeileh S, Curci F, de Libero C, Marrani E, Mastrolia MV, Pagnini I, Simonini G. Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience. Front Pediatr. 2022 Apr 12;10:851453. doi:10.3389/fped.2022.851453. PMID: 35498797; PMCID: PMC9039300.; Deodhar AA, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, Das Gupta A, Martin R, Safi J Jr, Porter B, Shete A, Rosenbaum JT. Incidence of uveitis in secukinumab‐treated patients with ankylosing spondylitis: pooled data analysis from three phase 3 studies. ACR open rheumatology. 2020;2(5):294–299. doi:10.1002/acr2.11139; Lasave AF, You C, Ma L, Abusamra K, Lamba N, Valdes Navarro M, Meese H, Foster CS. Long-term outcomes of rituximab therapy in patients with noninfectious posterior uveitis refractory to conventional immunosuppressive therapy. Retina. 2018;38(2):395–402. doi:10.1097/IAE.0000000000001563.; https://www.ophthalmojournal.com/opht/article/view/2098
-
2Academic Journal
Συγγραφείς: G. A. Davydova, T. A. Lisitsyna, L. A. Kovaleva, E. S. Sorozhkina, A. A. Zaitseva, A. A. Baisangurova, Г. А. Давыдова, Т. А. Лисицына, Л. А. Ковалева, Е. С. Сорожкина, А. А. Зайцева, А. А. Байсангурова
Πηγή: Ophthalmology in Russia; Том 19, № 3 (2022); 465-474 ; Офтальмология; Том 19, № 3 (2022); 465-474 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2022-3
Θεματικοί όροι: системный саркоидоз, immuno-inflammatory diseases, spondyloarthritis, rheumatoid arthritis, adult Still disease, juvenile idiopathic arthritis, systemic sarcoidosis, иммуновоспалительные заболевания, спондилоартрит, ревматоидный артрит, болезнь Стилла, ювенильный идиопатический артрит
Περιγραφή αρχείου: application/pdf
Relation: https://www.ophthalmojournal.com/opht/article/view/1908/1001; Foster C.S., Vitale A.T. Diagnosis and Treatment of Uveitis. 2nd Edition. New Delhi: Jaypee Brothers Medical Publishers; 2013. 1276 p.; Cаlamia K.T., Wilson F.C., Icen M., Crowson C.S., Gabriel S.E., Kremers H.M. Epidemiology and clinical characteristics of Beçcet’s disease in the US: a populationbased study. Arthritis Rheum. 2009;61(5):600–604. DOI:10.1002/art.24423; Панова И.Е., Дроздова Е.А. Увеиты. Руководство для врачей. М.: Медицинское информационное агентство; 2014. 144 с.; Nussenblatt R.B., Whitcup S.M. Uveitis: fundamentals and clinical practice. 4th ed. Maryland Heights: Elsevier Inc.; 2010.; Jakob E., Reuland M.S., Mackensen F., Harsch N., Fleckenstein M. Lorenz H.M., Max R., Becker M.D. Uveitis subtypes in a german interdisciplinary uveitis center-analysis of 1916 patients. J Rheumatol. 2009 Jan;36(1):127–136. DOI:10.3899/jrheum.080102; Дроздова Е.А. Вопросы классификации и эпидемиологии увеитов. Российский медицинский журнал. Клиническая офтальмология. 2016;16(3):155–159.; Chora I., Borges T., Dias C., Ourique C., Vilaça J., Ferreire S., Vaz-Marques P., Silva S., Dias C. Clinical Management of Uveitis in Systemic Rheumatic Autoimmune Diseases in Adults. Autoimmun Infec Dis. 2015;1(1): DOI:10.16966/2470-1025.104; Конькова А.Ю., Гаврилова Т.В., Черешнева М.В. Состояние заболеваемости увеитами в Пермском крае. Вестник Совета молодых ученых и специалистов Челябинской области. 2015;(4(11)2):31–35.; Кузнецова Т.И., Астахов Ю.С. Можно ли сократить долю увеитов неясной этиологии? Офтальмологические ведомости. 2019;12(3):21–30. DOI:10.17816/OV16369; Tran V.T., Auer C., Guex-Crosier Y., Pittet N., Herbort Carl P. Epidemiology of uveitis in Switzerland. Ocul Immunol Inflamm. 1994;2(3):169–176. DOI:10.3109/09273949409057073; Taylor W.J., Gladman D., Helliwell P., Marchesoni A, Mease P., Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–2673. DOI:10.1002/art.21972; Taylor W.J., Robinson P.C. Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis. Curr Rheumatol Rep. 2013 Apr;15(4):317. DOI:10.1007/s11926-013-0317-3; Turk M., Hayworth J., Nevskaya T., Pope J. The frequency of uveitis in patients with adult versus childhood spondyloarthritis. RMD Open. 2020 Aug;6(2):e001196. DOI:10.1136/rmdopen-2020-001196; Zeboulon N., Dougados M., Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008 Jul;67(7):955–959. DOI:10.1136/ard.2007.075754; Cantini F., Nannini C., Cassarà E., Kaloudi O., Niccoli L. Uveitis in Spondyloarthritis: An Overview. J Rheumatol Suppl. 2015 Nov;93:27–29. DOI:10.3899/jrheum.150630; Rosenbaum J.T. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol. 2015; 34: 999– 1002. DOI:10.1007/s10067-015-2960-8; Agrawal R.V., Murthy S., Sangwan V., Biswas J. Current approach in diagnosis and management of anterior uveitis. Indian J Ophthalmol. 2010;58(1):11–19. DOI:10.4103/0301-4738.58468; D’Ambrosio E.M., La Cava M., Tortorella P., Gharbiya M., Campanella M., Iannetti L. Clinical Features and Complications of the HLA-B27-associated Acute Anterior Uveitis: A Metanalysis. Semin Ophthalmol. 2017;32(6):689–701. DOI:10.3109/08820538.2016.1170158; Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of uveitis nomenclature (SUN) for reporting clinical data — results of the first international workshop. Am J Opthalmol. 2005;150:509–516. DOI:10.1016/j.ajo.2005.03.057; Herbort C.P. Appraisal, workup, and diagnosis of anterior uveitis: a practical approach. Middle East Afr J Ophthalmol. 2009;16(4):159–167. DOI:10.4103/09749233.58416; Rademacher J., Poddubnyy D., Pleyer U. Uveitis in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020 Sep 12;12:1759720X20951733. DOI:10.1177/1759720X20951733; Fong D.S., Raizman M.B. Spontaneous hyphema associated with anterior uveitis. Br J Ophthalmol. 1993;77(10):635–638. DOI:10.1136/bjo.77.10.635; Dodds E.M., Lowder C.Y., Meisler D.M. Posterior segment inflammation in HLAB27+ acute anterior uveitis: clinical characteristics. Ocular Immunology and Inflammation. 1999;7:85–92. DOI:10.1076/ocii.7.2.85.4015; Linssen A., Meenken C. Outcomes of HLAB27-positive and HLA-B27-negative acute anterior uveitis. Am J Ophthalmol. 1995;120(3):351–361. DOI:10.1016/s0002-9394(14)72165-8; Monnet D., Breban M., Hudry C., Dougados M., Brezin A.P. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology. 2004;111(4):802–809. DOI:10.1016/j.ophtha.2003.07.011; Rothova A., van Veenedaal W.G., Linssen A., Glasius E., Kijlstra A. Clinical features of acute anterior uveitis. Am J Ophthalmol. 1987 Feb 15;103(2):137–145. DOI:10.1016/s0002-9394(14)74218-7; Paiva E.S., Macaluso D.C., Edwards A., Rosenbaum J.T. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis. 2000 Jan;59(1):67–70. DOI:10.1136/ard.59.1.67; Fabiani C., Vitale A., Orlando I., Sota J., Capozzoli M., Franceschini R., Galeazzi M., Tosi G.M., Frediani B., Cantarini L. Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study. Internal and Emergency Medicine. 2017;12(7), 947–955. DOI:10.1007/s11739-017-1691-z; Kaçmaz R.O., Kempen J.H., Newcomb C., Gangaputra S., Daniel E., Jabs D.A., Foster S.C. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008 Dec;146(6):828–836. DOI:10.1016/j.ajo.2008.06.019.; Tayler M. Schwartz, Robert T. Keenan, Melissa B. Daluvoy. Ocular Involvement in Rheumatoid Arthritis. EyeNet Magazine November. 2016;Nov.:37–39.; Harthan J., Opitz D., Fromstein S., Morettin C. Diagnosis and treatment of anterior uveitis: optometric management. Clin Optom (Auckl). 2016;8:23–35. DOI:10.2147/OPTO.S72079; Kanski J., Pavesio C., Tuft S. Ocular inflammatory disease. Philadelphia: ElsevierMosby; 2006.; Felson D.T., Anderson J.J., Boers M. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–735. DOI:10.1002/art.1780380602; Zlatanović G., Veselinović D., Cekić S., Živković M., Đorđević-Jocić J., Zlatanovic M. Ocular manifestation of rheumatoid arthritis-different forms and frequency. Bosn J Basic Med Sci. 2010 Nov;10(4):323–327. DOI:10.17305/bjbms.2010.2680; Buyukavsar C., Karagoz E., Sonmez M., Kar T., Kaya A., Duzgun E., Yildirim Y. A Rare Ocular Manifestation of Adult Onset Still’s Disease: Purtscher’slike Retinopathy. Ocul Immunol Inflamm. 2018;26(2):286-291. DOI:10.1080/09273948.2016.1213857.; Yachoui R. Purtscher-like retinopathy associated with adult-onset Still disease. Retin Cases Brief Rep. 2018 Fall;12(4):379–381. DOI:10.1097/ICB.0000000000000515; Liu F.C., Chiang S.Y., Chang D.M., Lai J.H., Hou T.Y., Chen C.H. Purtscher’s-like retinopathy as an initial presentation of adult-onset Still’s disease: a case report and review of the literature. Clin Rheumatol. 2007 Jul;26(7):1204–1206. DOI:10.1007/s10067-006-0345-8; Heiligenhaus A., Heinz C., Edelsten C., Kotaniemi K., Minden K. Review for Disease of the Year: Epidemiology of Juvenile Idiopathic Arthritis and its Associated Uveitis: The Probable Risk Factors. Ocular Immunol Inflamm. 2013;21(3):180–191. DOI:10.3109/09273948.2013.791701; Pruunsild C., Uibo K., Liivamagi H., Tarraste T., Talvik T., Pelkonen P. Incidence of juvenile idiopathic arthritis in children in Estonia: a prospective population-based study. Scand J Rheumatol. 2007;36(1):7–13. DOI:10.1080/03009740601089259.; Riise Ø.R., Handeland K.S., Cvancarova M., Wathne K.O., Nakstad B., Abrahamsen T.G., Kirkhus E., Floto B. Incidence and characteristics of arthritis in Norwegian children: a population-based study. Pediatrics. 2008 Feb;121(2):e299–306. DOI:10.1542/peds.2007-0291; Solau-Gervais E., Robin C., Gambert C., Troller S., Danner S., Gombert B., Debiais F., Hankard R. Prevalence and distribution of juvenile idiopathic arthritis in a region of Western France. Joint Bone Spine. 2010 Jan;77(1):47–49. DOI:10.1016/j.jbspin.2009.11.002; Modesto C., Antón J., Rodriguez B., Bou R., Arnal C., Ros J., Tena X., Rodrigo C., Rotes I., Hermosilla E., Barcelo P. Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol. 2010 Nov;39(6):472–479. DOI:10.3109/03009741003742722; Ravelli A., Felici E., Magni-Manzoni S., Pistorio A., Novarini C., Bozzola E., Viola S., Martini A. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. 2005 Mar;52(3):826–832. DOI:10.1002/art.20945; Heiligenhaus A., Niewerth M., Ganser G., Heinz C., Minden K. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007 Jun;46(6):1015–1019. DOI:10.1093/rheumatology/kem053; Kotaniemi K., Kautiainen H., Karma A., Aho K. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology. 2001 Nov;108(11):2071–2075. DOI:10.1016/s0161-6420(01)00773-4; Burgos-Vargas R., Pacheco-Tena C., Vázquez-Mellado J. The juvenile-onset spondyloarthritides: rationale for clinical evaluation. Best Pract Res Clin Rheumatol. 2002 Sep;16(4):551–572. DOI:10.1053/berh.2002.0247; Durrani O.M., Tehrani N.N., Marr J.E., Moradi P., Stavrou P., Murray P.I. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004 Sep;88(9):1159– 1162. DOI:10.1136/bjo.2003.037226; Lardenoye C.W., van Kooij B., Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006 Aug;113(8):1446–1449. DOI:10.1016/j.ophtha.2006.03.027; Rothova A., Suttorp-van Schulten M.S., Frits Treffers W., Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336. DOI:10.1136/bjo.80.4.332; Taylor S.R., Lightman S.L., Sugar E.A., Jaffe G.J., Freeman W.R., Altaweel M.M., Kozak I., Holbrook J.T., Jabs D.A., Kempen J.H. The impact of macular edema on visual function in intermediate, posterior, and panuveitis. Ocul Immunol Inflamm. 2012 Jun;20(3):171–181. DOI:10.3109/09273948.2012.658467; De Boer J., Steijaert A., van den Bor R., Stellato R., Ossewaarde-van Norel J. Development of macular edema and impact on visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2015 Feb;23(1):67–73. DOI:10.3109/09273948.2013.871566; Tristano A.G. Neurological adverse events associated with anti-tumor necrosis factor α treatment. J Neurol. 2010 Sep;257(9):1421–1431. DOI:10.1007/s00415-0105591-7; Thorne J.E., Woreta F., Kedhar S.R., Dunn J.P., Jabs D.A. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007 May;143(5):840–846. DOI:10.1016/j.ajo.2007.01.033; Woreta F., Thorne J.E., Jabs D.A., Kedhar S.R., Dunn J.P. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007 Apr;143(4):647–655. DOI:10.1016/j.ajo.2006.11.025; Ohara K., Okubo A., Sasaki H., Kamata K. Intraocular manifestations of systemic sarcoidosis. Jpn J Ophthalmol. 1992;36(4):452–457. PMID: 1289622; Chumbley L.C., Kearns T.P. Retinopathy of sarcoidosis. Am J Ophthalmol. 1972 Jan;73(1):123–131. DOI:10.1016/0002-9394(72)90314-5.; Cook B.E. Jr., Robertson D.M. Confluent choroidal infiltrates with sarcoidosis. Retina. 2000;20(1):1–7. DOI:10.1097/00006982-200001000-00001; Desai U.R., Tawansy K.A., Joondeph B.C., Schiffman R.M. Choroidal granulomas in systemic sarcoidosis. Retina. 2001;21(1):40–47. DOI:10.1097/00006982200102000-00007; Thorne J.E., Brucker A.J. Choroidal white lesions as an early manifestation of sarcoidosis. Retina. 2000;20(1):8–15. DOI:10.1097/00006982-200001000-00002; Herbort C.P., Rao N.A., Mochizuki M.; members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009 May-Jun;17(3):160–169. DOI:10.1080/09273940902818861; Acharya N.R., Browne E.N., Rao N., Mochizuki M., International Ocular Sarcoidosis Working Group. Distinguishing Features of Ocular Sarcoidosis in an International Cohort of Uveitis Patients. Ophthalmology. 2018 Jan;125(1):119–126. DOI:10.1016/j.ophtha.2017.07.006; Matsou A., Tsaousis K.T. Management of chronic ocular sarcoidosis: challenges and solutions. Clin Ophthalmol. 2018 Mar 19;12:519–532. DOI:10.2147/OPTH. S128949; Birnbaum A.D., Oh F.S., Chakrabarti A., Tessler H.H., Goldstein D.A. Clinical features and diagnostic evaluation of biopsy-proven ocular sarcoidosis. Arch Ophthalmol. 2011 Apr;129(4):409–413. DOI:10.1001/archophthalmol.2011.52; Jabs D.A., Johns C.J. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol. 1986 Sep 15;102(3):297–301. DOI:10.1016/0002-9394(86)90001-2; Dammacco R., Biswas J., Kivelä T.T., Zito F.A., Leone P., Mavilio A., Sisto D., Alessio G., Dammacco F. Ocular sarcoidosis: clinical experience and recent pathogenetic and therapeutic advancements. Int Ophthalmol. 2020 Dec;40(12):3453–3467. DOI:10.1007/s10792-020-01531-0; Yang S.J., Salek S., Rosenbaum J.T. Ocular sarcoidosis: new diagnostic modalities and treatment. Current Opinion in Pulmonary Medicine. 2017;23(5):458–467. DOI:10.1097/MCP.0000000000000409; Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. 2000;84(1):110– 116. DOI:10.1136/bjo.84.1.110; Pasadhika S., Rosenbaum J.T. Ocular Sarcoidosis. Clin Chest Med. 2015 Dec;36(4):669–683. DOI:10.1016/j.ccm.2015.08.009; Davuluri G., Reed G.F., Smith J.A., Rubin B., Nussenblatt R.B., Levy-Clarke G.A. Ocular Complications of Sarcoidosis. Invest. Ophthalmol. Vis. Sci. 2006;47(13):585.; Stavrou P., Linton S., Young D.W., Murray P.I. Clinical diagnosis of ocular sarcoidosis. Eye (Lond). 1997;11 (Pt 3):365–370. DOI:10.1038/eye.1997.77; https://www.ophthalmojournal.com/opht/article/view/1908
-
3Academic Journal
Συγγραφείς: G. A. Davydova, T. A. Lisitsyna, L. A. Kovaleva, E. S. Sorozhkina, A. A. Zaitseva, A. A. Baisangurova, Г. А. Давыдова, Т. А. Лисицына, Л. А. Ковалева, Е. С. Сорожкина, А. А. Зайцева, А. А. Байсангурова
Πηγή: Ophthalmology in Russia; Том 19, № 4 (2022); 719-726 ; Офтальмология; Том 19, № 4 (2022); 719-726 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2022-4
Θεματικοί όροι: аутовоспалительные синдромы, immune-inflammatory diseases, Behcet’s syndrome, systemic lupus erythematosis, Vogt—Koyanagi—Harada syndrome, autoinflammatory syndrome, иммуновоспалительные заболевания, болезнь Бехчета, системная красная волчанка, синдром Фогта — Коянаги — Харада
Περιγραφή αρχείου: application/pdf
Relation: https://www.ophthalmojournal.com/opht/article/view/1974/1035; Cаlamia K.T., Wilson F.C., Icen M., Crowson C.S., Gabriel S.E., Kremers H.M. Epidemiology and clinical characteristics of Beçcet’s disease in the US: a population based study. Arthritis Rheum. 2009;61(5):600–604. DOI:10.1002/art.24423; McCannel C.A., Holland G.N., Helm C.J., Cornell P.J., Winston J.V., Rimmer T.G., UCLA Community Based Uveitis Study Group. Causes of uveitis in the general practice of ophthalmology. Am J Ophthalmol. 1996 Jan;121(1):35–46. DOI:10.1016/s0002 9394(14)70532 x; Jakob E., Reuland M.S., Mackensen F., Harsch N., Fleckenstein M. Lorenz H.M., Max R., Becker M.D. Uveitis subtypes in a german interdisciplinary uveitis center analysis of 1916 patients. J Rheumatol. 2009 Jan;36(1):127–136. DOI:10.3899/jrheum.080102; Chora I., Borges T., Dias C., Ourique C., Vilaça J., Ferreire S., Vaz Marques P., Silva S., Dias C. Clinical Management of Uveitis in Systemic Rheumatic Autoimmune Diseases in Adults. Autoimmun Infec Dis. 2015;1 (1): DOI:10.16966/2470 1025.104; Конькова А.Ю., Гаврилова Т.В., Черешнева М.В. Состояние заболеваемости увеитами в Пермском крае. Вестник Совета молодых ученых и специалистов Челябинской области. 2015;2(4(11)):31–35.; Кузнецова Т.И., Астахов Ю.С. Можно ли сократить долю увеитов неясной этиологии? Офтальмологические ведомости. 2019;12(3):21–30. DOI:10.17816/OV16369; Tran V.T., Auer C., Guex Crosier Y., Pittet N., Herbort Carl P. Epidemiology of uveitis in Switzerland. Ocul Immunol Inflamm. 1994;2(3):169–176. DOI:10.3109/09273949409057073; Hamdan A., Mansour W., Uthman I., Masri A.F., Nasr F., Arayssi T. Behçet’s disease in Lebanon: clinical profile, severity and two decade comparison. Clin Rheumatol. 2006 May;25(3):364–367. DOI:10.1007/s10067 005 0058 4; Mousa A.R., Marafie A.A., Rifai K.M., Dajani A.I., Mukhtar M.M. Behçet’s disease in Kuwait, Arabia. A report of 29 cases and a review. Scand J Rheumatol. 1986;15(3):310–332. DOI:10.3109/03009748609092599; Fabiani C., Vitale A., Orlando I., Sota J., Capozzoli M., Franceschini R., Galeazzi M., Tosi G.M., Frediani B., Cantarini L. Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study. Internal and Emergency Medicine. 2017;12(7):947–955. DOI:10.1007/s11739 017 1691 z; Kaçmaz R.O., Kempen J.H., Newcomb C., Gangaputra S., Daniel E., Jabs D.A., Foster S.C. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008 Dec;146(6):828–836. DOI:10.1016/j.ajo.2008.06.019; Verity D.H., Wallace G.R., Vaughan R.W., Stanford M.R. Behçet’s disease: from Hippocrates to the third millennium. Br J Ophthalmol. 2003 Sep;87(9):1175–1183. DOI:10.1136/bjo.87.9.1175; Taylor S.R., Singh J., Menezo V., Wakefield D., McCluskey P., Lightman S. Behçet disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol. 2011 Dec;152(6):1059–1066. DOI:10.1016/j.ajo.2011.05.032; Desbois A.C., Terrada C., Cacoub P., Bodaghi B., Saadoun D. Les manifestations oculaires de la maladie de Behçet [Ocular manifestations in Behçet’s disease]. Rev Med Interne. 2018 Sep;39(9):738–745. French. DOI:10.1016/j.revmed.2018.02.022; Abd El Latif E., Abdel Kader Fouly Galal M., Tawfik M.A., Elmoddather M., Nooreldin A., Shamselden Yousef H. Pattern of Uveitis Associated with Behçet’s Disease in an Egyptian Cohort. Clin Ophthalmol. 2020;14:4005–4014. Published 2020 Nov 20. DOI:10.2147/OPTH.S287298; Khairallah M., Accorinti M., Muccioli C., Kahloun R., Kempen J.H. Epidemiology of Behçet disease. Ocul Immunol Inflamm. 2012 Oct;20(5):324–335. DOI:10.3109/09273948.2012.723112; Davatchi F., Shahram F., Chams Davatchi C., Shams H., Abdolahi B.S., Nadji A., Faezi T., Akhlaghi M., Ghodsi Z., Karimi N., Kavosi H., Mohtasham N., Masoumi M., Shadmanfar S., Mousavi M. Behcet’s disease in Iran: Analysis of 7641 cases. Mod Rheumatol. 2019 Nov;29(6):1023–1030. DOI:10.1080/14397595.2018.1558752; Tugal Tutkun I., Onal S., Yaycioglu A.R., Altunbas H.H., Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–380. DOI:10.1016/j.ajo.2004.03.022; Yang P., Fang W., Meng Q., Ren Y., Xing L., Kijlstra A. Clinical features of Chinese patients with Behçet’s disease. Ophthalmology. 2008 Feb;115(2):312–318.e4. DOI:10.1016/j.ophtha.2007.04.056; Namba K., Goto H., Kaburaki T., Kitaichi N., Mizuki N., Asukata Y., Fujino Y., Meguro A., Sakamoto S., Shibuya E., Yokoi K., Ohno S. A Major Review: Current Aspects of Ocular Behçet’s Disease in Japan. Ocul Immunol Inflamm. 2015;23 Suppl 1:S1–23. DOI:10.3109/09273948.2014.981547; Foster C.S., Vitale A.T. Diagnosis and Treatment of Uveitis. 2nd Edition. New Delhi: Jaypee Brothers Medical Publishers; 2013. P. 863–864.; Hayashi T., Mizuki N. Ocular Manifestations in Behçet’s Disease. JMAJ. 2006:49(7–8):260–268.; Onal S., Tugal Tutkun I. Behçet Disease. In: Biswas J., Majumder P.D. (eds). Uveitis: An Update. India: Springer. 2016. P. 17–31.; Sota J., Cantarini L., Vitale A. Long Term Outcomes of Behçet’s Syndrome Related Uveitis: A Monocentric Italian Experience May 2020 Mediators of Inflammation 2020;8:1–8. DOI:10.1155/2020/6872402; Çakar Özdal P. Behçet’s Uveitis: Current Diagnostic and Therapeutic Approach. Turk J Ophthalmol. 2020 Jun 27;50(3):169–182. DOI:10.4274/tjo.galenos.2019.60308; Pathanapitoon K., Kunavisarut P., Saravuttikul F. A., Rothova A. Ocular manifestations and visual outcomes of Behçet’s uveitis in a Thai population. Ocular Immunologyand Inflammation. 2019:27(1):2–6. DOI:10.1080/09273948.2017.1351570; Wakefield D., Cunningham E.T., Tugal Tutkun I., Khairallah M., Ohno S., Zierhut M. Controversies in Behçet disease. Ocul Immunol Inflamm. 2012;20(1):6–11. DOI:10.3109/09273948.2011.649153; Ozdal P.C., Ortaç S., Taşkintuna I., Firat E. Posterior segment involvement in ocular Behçet’s disease. Eur J Ophthalmol. 2002 Sep Oct;12(5):424–431. DOI:10.1177/112067210201200514; Sachdev N., Kapali N., Singh R., Gupta V., Gupta A. Spectrum of Behçet’s disease in the Indian population. Int Ophthalmol. 2009;29(6):495–501. DOI:10.1007/s10792 008 9273 8; Tugal Tutkun I. Behçet’s Uveitis. Middle East Afr J Ophthalmol. 2009;16:219–224. DOI:10.4103/0974-9233.58425; Rosenbaum J.T., Sibley C.H., Lin P. Retinal vasculitis. Curr Opin Rheumatol. 2016 May;28(3):228–235. DOI:10.1097/BOR.0000000000000271; Pantanelli S.M., Khalifa Y.M. Retinal manifestations of autoimmune and inflammatory disease. Int Ophthalmol Clin. 2012 Winter;52(1):25–46. DOI:10.1097/IIO.0b013e31823bbbe9; Stübiger N., Zierhut M., Kötter I. Ocular manifestations in Behçet’s disease. In: Zierhut M, Ohno S, editors. Immunology of Behçet’s Disease. Lisse, Netherlands: Swets & Zeitlinger; 2003. P. 36–45.; Kahloun R., Ben Yahia S., Mbarek S., Attia S., Zaouali S., Khairallah M. Macular involvement in patients with Behçet’s uveitis. J Ophthalmic Inflamm Infect. 2012;2(3):121–124. DOI:10.1007/s12348-012-0075-9; Krause L., Köhler A.K., Altenburg A., Papoutsis N., Zouboulis C.C., Pleyer U., Stroux A., Foerster M.H. Ocular involvement in Adamantiades Behçet’s disease in Berlin, Germany. Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):661–666. DOI:10.1007/s00417-008-0983-4; Kidd D.P. Optic neuropathy in Behçet’s syndrome. J Neurol. 2013 Dec;260(12):3065–3070. DOI:10.1007/s00415 013 7070 4; Khanfir M.S., Belfeki N., Said F., Ben Salem T., Ben Ghorbel I., Lamloum M., Hamzaoui A., Houman M.H. Inflammatory optic neuropathy in Behçet’s disease. Reumatismo. 2015 Dec 23;67(4):156–160. DOI:10.4081/reumatismo.2015.835; Siva A., Kantarci O.H., Saip S., Altintas A., Hamuryudan V., Islak C., Koçer N., Yazici H. Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001 Feb;248(2):95–103. DOI:10.1007/s004150170242; Kaçmaz R.O., Kempen J.H., Newcomb C., Gangaputra S., Daniel E., Levy Clarke G.A., Nussenblatt R.B., Rosenbaum J.T., Suhler E.B., Thorne J.E., Jabs D.A., Foster C.S.; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008 Dec;146(6):828–836. DOI:10.1016/j.ajo.2008.06.019; Zink J.M., Singh Parikshak R., Johnson C.S., Zacks D.N. Hypopyon uveitis associated with systemic lupus erythematosus and antiphospholipid antibody syndrome. Graefes Arch Clin Exp Ophthalmol. 2005 Apr;243(4):386–388. DOI:10.1007/s00417-004-1022-8; Albert D.M., Miller J., Azar D., Young L.H. Albert and Jakobiec’s Principles and Practice of Ophthalmology. 1994. WB Saunders: Philadelphia, 2894–2901.; Yacoub Wasef S.Z. Gender differences in systemic lupus erythematosus. Gend Med. 2004 Aug;1(1):12–17. DOI:10.1016/s1550 8579(04)80006 8; Ushiyama O., Ushiyama K., Koarada S., Tada Y., Suzuki N., Ohta A., Oono S., Nagasawa K. Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis. 2000 Sep;59(9):705–708. DOI:10.1136/ard.59.9.705; Bishko F. Retinopathy in systemic lupus erythematosus. A case report and review of the literature. Arthritis Rheum. 1972 Jan Feb;15(1):57–63. DOI:10.1002/art.1780150109; Durukan A.H., Akar Y., Bayraktar M.Z., Dinc A., Sahin O.F. Combined retinal artery and vein occlusion in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Can J Ophthalmol. 2005 Feb;40(1):87–89. DOI:10.1016/s0008-4182(05)80126-7; Baglio V., Gharbiya M., Balacco Gabrieli C., Mascaro T., Gangemi C., Di Franco M., Pistolesi V., Morabito S., Pecci G., Pierucci A. Choroidopathy in patients with systemic lupus erythematosus with or without nephropathy. J Nephrol. 2011 Jul Aug;24(4):522–529. DOI:10.5301/JN.2011.6244; Feinglass E.J., Arnett F.C., Dorsch C.A., Zizic T.M., Stevens M.B. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore). 1976 Jul;55(4):323–339. DOI:10.1097/00005792 197607000 00004; Cunningham E.T. Jr., Alfred P.R., Irvine A.R. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology. 1996 Dec;103(12):2081–2090. DOI:10.1016/s0161 6420(96)30385 0; Nguyen Q.D., Uy H.S., Akpek E.K., Harper S.L., Zacks D.N., Foster C.S. Choroidopathy of systemic lupus erythematosus. Lupus. 2000;9(4):288–298. DOI:10.1191/096120300680199024; Sivaraj R.R., Durrani O.M., Denniston A.K., Murray P.I., Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007 Dec;46(12):1757–1762. DOI:10.1093/rheumatology/kem173; Karim S., Majithia V. Devic’s syndrome as initial presentation of systemic lupus erythematosus. Am J Med Sci. 2009 Sep;338(3):245–247. DOI:10.1097/MAJ.0b013e3181a8be1d; Jacobi C., Stingele K., Kretz R., Hartmann M., Storch Hagenlocher B., Breitbart A., Wildemann B. Neuromyelitis optica (Devic’s syndrome) as first manifestation of systemic lupus erythematosus. Lupus. 2006;15(2):107–109. DOI:10.1191/0961203306lu2265cr; Adawi M., Bisharat B., Bowirrat A. Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO — Devic’s Disease): Clinic Pathological Report and Review of the Literature. Clin Med Insights Case Rep. 2014 Jun 2;7:41–47. DOI:10.4137/CCRep.S15177; Jensen J.L., Bergem H.O., Gilboe I.M., Husby G., Axéll T. Oral and ocular sicca symptoms and findings are prevalent in systemic lupus erythematosus. Journal of Oral Pathology and Medicine. 1999:28(7)317–322. DOI:10.1111/j.1600 0714.1999.tb02047.x; Sitaula R., Shah D.N., Singh D. The spectrum of ocular involvement in systemic lupus erythematosus in a tertiary eye care center in Nepal. Ocul Immunol Inflamm. 2011 Dec;19(6):422–425. DOI:10.3109/09273948.2011.610023; Palejwala N.V., Walia H.S., Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012;2012:290898. DOI:10.1155/2012/290898; Silpa archa S., Lee J.J., Foster C.S. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2016 Jan;100(1):135–141. DOI:10.1136/bjophthal mol 2015 306629; Dollfus H., Häfner R., Hofmann H.M., Russo R.A., Denda L., Gonzales L.D., De-Cunto C., Premoli J., Melo Gomez J., Jorge J.P., Vesely R., Stubna M., Dufier J.L., Prieur A.M. Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood. Arch Ophthalmol. 2000 Oct;118(10):1386–1392. DOI:10.1001/archopht.118.10.1386; Abad S., Wieërs G., Colau D., Wildmann C., Delair E. Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt Koyanagi Harada patient. Mol Vis. 2014 Jul 2;20:956–969. PMID: 24991188; PMCID: PMC4077848; Liu B., Deng T., Zhu L., Zhong J. Association of human leukocyte antigen (HLA) DQ and HLA DQA1/DQB1 alleles with Vogt Koyanagi Harada disease: A systematic review and meta analysis. Medicine (Baltimore). 2018 Feb;97(7):e9914. DOI:10.1097/MD.0000000000009914; Rao N.A., Sukavatcharin S., Tsai J.H. Vogt Koyanagi Harada disease diagnostic criteria. Int Ophthalmol. 2007 Apr Jun;27(2 3):195–199. DOI:10.1007/s10792 006 9021 x; Mota L.A., Santos A.B. Vogt Koyanagi Harada’s syndrome and its multisystem involvement. Rev Assoc Med Bras (1992). 2010 Sep Oct;56(5):590–595. English, Portuguese. DOI:10.1590/s0104 42302010000500023; Balci O., Gasc A., Jeannin B., Herbort C.P. Jr. Enhanced depth imaging is less suited than indocyanine green angiography for close monitoring of primary stromal choroiditis: a pilot report. Int Ophthalmol. 2017 Jun;37(3):737–748. DOI:10.1007/s10792-016-0303-7; Lodhi S.A., Reddy J.L., Peram V. Clinical spectrum and management options in Vogt Koyanagi Harada disease. Clin Ophthalmol. 2017 Aug 7;11:1399–1406. DOI:10.2147/OPTH.S134977; Attia S., Khochtali S., Kahloun R., Zaouali S., Khairallah M. Vogt–Koyanagi–Harada disease. Expert Review of Ophthalmology. 2012;7:565–585. DOI:10.1586/eop.12.63; Bacsal K., Wen D.S., Chee S.P. Concomitant choroidal inflammation during anterior segment recurrence in Vogt Koyanagi Harada disease. Am J Ophthalmol. 2008 Mar;145(3):480–486. DOI:10.1016/j.ajo.2007.10.012; Takemoto Y., Namba K., Mizuuchi K., Iwata D., Uno T., Ohno S., Hirooka K., Hashimoto Y., Saito W., Sugiyama K., Ishida S. Choroidal circulation impairment during the anterior recurrence of Vogt Koyanagi Harada disease confirmed with indocyanine green angiography and laser speckle flowgraphy. Acta Ophthalmol. 2016 Nov;94(7):e629–e636. DOI:10.1111/aos.13024; Taylor S., Lightman S. Recurrent anterior uveitis in patients with Vogt Koyanagi Harada syndrome. Arch Ophthalmol. 2004 Jun;122(6):922–923. DOI:10.1001/archopht.122.6.922; Tagawa Y., Namba K., Mizuuchi K., Takemoto Y., Iwata D., Uno T., Fukuhara T., Hirooka K., Kitaichi N., Ohno S., Ishida S. Choroidal thickening prior to anterior recurrence in patients with Vogt Koyanagi Harada disease. Br J Ophthalmol. 2016 Apr;100(4):473–477. DOI:10.1136/bjophthalmol-2014 306439; Magliyah M.S., Al Fakhri A.S., Al Dhibi H.A. Proliferative retinopathy as a feature of Vogt Koyanagi Harada Disease: a report of two cases. BMC Ophthalmol. 2020:20:470. DOI:10.1186/s12886-020-01736-y; https://www.ophthalmojournal.com/opht/article/view/1974
-
4Academic Journal
Συγγραφείς: T. A. Lisitsyna, Z. S. Alekberova, G. A. Davydova, T. M. Reshetnyak, L. A. Katargina, E. L. Nasonov, Т. А. Лисицына, З. С. Алекберова, Г. А. Давыдова, Т. М. Решетняк, Л. А. Катаргина, Е. Л. Насонов
Συνεισφορές: Работа выполнена в рамках научной темы рег. № НИОКТР АААА-А19-119021190151-3.
Πηγή: Rheumatology Science and Practice; Vol 58, No 4 (2020); 428-436 ; Научно-практическая ревматология; Vol 58, No 4 (2020); 428-436 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: генно-инженерные биологические препараты, immune-mediated inflammatory diseases, spondyloarthritis, Behcet’s disease, juvenile idiopathic arthritis, biologics, иммуновоспалительные заболевания, спондилоартрит, болезнь Бехчета, ювенильный идиопатический артрит, глюкокортикоиды, метотрексат
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2932/2010; Неинфекционные увеиты. Клинические рекомендации ООО «Ассоциация врачей-офтальмологов», ООО «Общество офтальмологов России», 2019 г. http://avo-portal.ru/doc/fkr/development/item/343-neinfektsionnye-uveity; https://oor.ru/vracham/klrek/proekt-klinicheskikh-rekomendatsiyneinfektsionnye-uveity-dlya-obsuzhdeniya/; Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-Kearney ML, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Semin Arthritis Rheum 2019; 49(3): 438-445 doi:10.1016/j.semarthrit.2019.06.004; Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardiza-tion of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-16. doi:10.1016/j.ajo.2005.03.057; Deschenes J, Murray P, Rao N, Nussenblatt R. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis. Ocular Immunology and Inflammation. 2008; 16(1-2): 1-2. doi:10.1080/09273940801899822; Tsirouki T, Dastiridou A, Symeonidis C, et al. A Focus on the Epidemiology of Uveitis. Ocul Immunol Inflamm. 2018; 26 (1): 2-16. doi:10.1080/09273948.2016.1196713; Chora I, Borges T, Dias C, Ourique C, Vilaça J, et al. Clinical Management of Uveitis in Systemic Rheumatic Autoimmune Diseases in Adults. Autoimmun Infec Dis. 2015; 1 (1): doi http://dx.doi.org/10.16966/2470-1025.104; Juanola X, Loza Santamaria E, Cordero-Coma M. Sentinel Working Group. Description and prevalence of spondyloarthritis in patients with anterior uveitis: the SENTINEL Interdisciplinary Collaborative Project. Ophthalmology. 2016; 123: 1632–6 https://doi.org/10.1016/j.ophtha.2016.03.010; Forrester JV, Kuffova L, Dick AD. Autoimmunity, Autoinflammation, and Infection in Uveitis. Am J Ophthalmology. 2018;189:77-85. doi:10.1016/j.ajo.2018.02.019; Zhong Z, Su G, Kijlstra A, Yang P. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2020;100866. doi:10.1016/j.preteyeres.2020.100866; Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018; 125 (5): 757–773. doi:10.1016/j.ophtha.2017.11.017; Valenzuela RA, Flores I, Urrutia B, et al. New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview. Front Pharmacol. 2020;11:655. Published 2020 May 8. doi:10.3389/fphar.2020.00655; Choi J, Hawley DP, Ashworth J, Edelsten C, Bossuyt ASAM. An update on the modern management of paediatric uveitis. Br J Ophthalmol. 2019;103(12):1685-1689. doi:10.1136/bjophthalmol-2019-314212; Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 2019;19(5):477-490. doi:10.1080/14712598.2019.1595578; Hassan M, Karkhur S, Bae JH, Halim MS, Ormaechea MS, Onghanseng N, Nguyen NV, Afridi R, Sepah YJ, Do DV, Nguyen QD. New therapies in development for the management of non-infectious uveitis: A review. Clin. Experiment. Ophthalmol. 2019; 47: 396–417. doi:10.1111/ceo.13511; Kempen JH, Daniel E, Gangaputra S, Dreger K, Jabs DA, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008; 15 (1): 47-55 doi:10.1080/09286580701585892; Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011; 16 (2): 309-322. doi:10.1517/14728214.2011.537824.; Schultz C. Voclosporin as a treatment for noninfectious uveitis. Ophthalmol Eye Dis. 2013; 5: 5-10. doi:10.4137/OED.S7995; Leal I, Rodrigues FB, Sousa DC, et al. Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and MetaAnalysis of Randomized Controlled Trials. Front Med (Lausanne). 2019;6:104. doi:10.3389/fmed.2019.00104; Ming S, Xie K, He H, Li Y, Lei B. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther. 2018;12:2005-2016. doi:10.2147/DDDT.S160431; Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019;30(3):138-150. doi:10.1097/ICU.0000000000000562; Ahmed A, Foster CS. Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis. Ophthalmic Res. 2019;61(1):44-50. doi:10.1159/000486791; Urruticoechea-Arana A, Cobo-Ibáñez T, Villaverde-García V, et al. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet’s disease associated uveitis: a systematic review. Rheumatol Int. 2019;39(1):47-58. doi:10.1007/s00296-018-4193-z; Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. 2019;9(1):17. doi:10.1186/s12348- 019-0182-y; Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. Am J Ophthalmol. 2017;183:71-80. doi:10.1016/j.ajo.2017.08.019; Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU): The Phase 2 SATURN Study. Ophthalmology. 2019;126(3):428-437. doi:10.1016/j.ophtha.2018.09.044; Dick AD, Tugal-Tutkun l, Foster S, Zierhut M, Liew SHM, Bezlyak V, Androudi S. Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials. Ophthalmology. 2013; 120: 777-787 https://doi.org/10.1016/j.ophtha.2012.09.040; Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73-84. doi:10.1016/S0140-6736(16)31591-4; Molto A, Sieper J. Peripheral spondyloarthritis: Concept, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2018;32(3):357-368. doi:10.1016/j.berh.2019.02.010; Rudwaleit M, Landewe R, van der Heijde D, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68: 777-83. doi:10.1136/ard.2009.1082335; Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spon-dyloarthritis in general. Ann Rheum Dis. 201; 70 (1): 25-31. doi:10.1136/ard.2010.133645; Murray PI, Rauz S. The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis. Best Pract Res Clin Rheumatol. 2016;30(5):802- 825. doi:10.1016/j.berh.2016.10.007; Годзенко АА, Бочкова АГ, Румянцева ОА и др. Течение и исходы увеита у больных анкилозирующим спондилитом. Научно-практическая ревматология. 2014;52(5):520–525. doi:10.14412/1995-4484-2014-520-525.; Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol. 2017;31(6):846-862. doi:10.1016/j.berh.2018.08.002; Mitulescu TC, Trandafir M, Dimăncescu MG, et al. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy? Rom J Ophthalmol. 2018;62(2):114-122; Mugheddu C, Atzori L, Del Piano M, et al. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther. 2017; 30(5): e12527. doi:10.1111/dth.12527; Бекетова ТВ. Системные васкулиты. Российские клинические рекомендации. Ревматология. под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017. С.180–205.; Watts RA, Robson J. Introduction, epidemiology and classification of vasculitis. Best Pract Res Clin Rheumatol. 2018;32(1):3- 20. doi:10.1016/j.berh.2018.10.003; Tugal-Tutkun I. Systemic vasculitis and the eye. Curr Opin Rheumatol. 2017;29(1):24-32. doi:10.1097/BOR.0000000000000345; Лисицына ТА, Алекберова ЗС, Голоева РГ, Давыдова ГА. Болезнь Бехчета: клинические проявления, современные принципы диагностики и терапии. Научно-практическая ревматология. 2019; 57(5): 553-563. doi:10.14412/1995-4484-2019-553-563; Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view [published correction appears in Nat Rev Rheumatol. 2018 Jan 24;14 (2):119]. Nat Rev Rheumatol. 2018;14(2):107-119. doi:10.1038/nrrheum.2017.208; Ksiaa I, Abroug N, Kechida M, et al. Eye and Behçet’s disease. J Fr Ophtalmol. 2019;42(4):e133-e146. doi:10.1016/j.jfo.2019.02.002; Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808-818. doi:10.1136/annrheumdis-2018-213225; Лисицына ТА, Алекберова ЗС, Голоева РГ. Новые рекомендации по ведению пациентов с болезнью/синдромом Бехчета (EULAR, 2018). Научно-практическая ревматология. 2019; 57(2):133-141. doi:10.14412/1995-4484-2019-133-141; Uke P, Gorodkin R, Beare N. Biologic therapy for Behçet’s uveitis: a systematic review. Br J Ophthalmol. 2020;104(8):1045-1051. doi:10.1136/bjophthalmol-2019-314154; Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behcet disease responsive to anakinra. Ann Intern Med. 2008; 149 (4):284-286. doi:10.7326/0003-4819-149-4-200808190-00018; Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juve-nile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis. 2012; 71(9): 1589-1591. doi:10.1136/annrheumdis-2012-201383; Lopalco G, Fabiani C, Venerito V, Lapadula G, Iannone F, Cantarini L. Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behcet’s disease. Clin Exp Rheumatol. 2017; 35 (6 suppl 108):130-131; Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with Behcet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and openlabel extension study. Ocul Immunol Inflamm. 2018; 25:1-11. doi:10.1080/09273948.2017.1421233; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38. doi:10.1016/S0140-6736(16)30173-8; Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138-2149. doi:10.1016/S0140-6736(11)60244-4; Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322. doi:10.1016/j.clim.2019.108322; Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16(1):46. doi:10.1186/s12969-018-0255-8; Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107-1117. doi:10.1136/annrheumdis-2018-213131; Катаргина ЛА, Бржеский ВВ, Гусева МР, Денисова ЕВ, Дроздова ЕА, Жукова ОВ, Никишина ИП, Старикова АВ. Федеральные клинические рекомендации «Диагностика и лечение увеитов, ассоциированных с ювенильным идиопатическим артритом». Российская педиатрическая офтальмология. 2016; 11 (2): 102-111. doi:10.18821/1993-1859-2016-11-2-102-111; Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C, et al. Update of the evidence based, interdisciplinary guideline for antiinflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism. 2019; 49: 43-55. https://doi.org/10.1016/j.semarthrit.2018.11.004; Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: новые горизонты диагностики и терапии. Научнопрактическая ревматология. 2020; 58(1): 5-14. doi:10.14412/1995-4484-2020-5-14; Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-2358. doi:10.1016/S0140-6736(19)30546-X; Cunningham ET, Tabbara KF, Zierhut M. Systemic Lupus Erythematosus and the Eye. Ocul Immunol Inflamm. 2018;26(8):1143-1145. doi:10.1080/09273948.2018.1539589; Krainer J, Siebenhandl S, Weinhäusel A. Systemic autoinflammatory diseases. J Autoimmun. 2020;109:102421. doi:10.1016/j. jaut.2020.102421; Georgin-Lavialle S, Ducharme-Benard S, Sarrabay G, Savey L, Grateau G, Hentgen V. Systemic autoinflammatory diseases: Clinical state of the art. Best Pract Res Clin Rheumatol. 2020;101529. doi:10.1016/j.berh.2020.101529; Салугина СО, Кузьмина НН, Федоров ЕС. Аутовоспалительные синдромы – «новая» мультидисциплинарная проблема педиатрии и ревматологии. Педиатрия 2012; 91 (5): 120-132.; Hausmann JS. Targeting cytokines to treat autoinflammatory diseases. Clin Immunol. 2019;206:23-32. doi:10.1016/j.clim.2018.10.016
-
5Academic Journal
Συγγραφείς: НАСОНОВ Е.Л., ЕЛИСЕЕВ М.С.
Περιγραφή αρχείου: text/html
-
6Academic Journal
Πηγή: Научно-практическая ревматология.
Θεματικοί όροι: ИММУНОВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ,АУТОВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ,ЦИТОКИНЫ,ИНФЛАММАСОМА,ИНТЕРЛЕЙКИН 1,ИНГИБИТОРЫ ИНТЕРЛЕЙКИНА 1,IMMUNOINFLAMMATORY DISEASES,AUTOINFLAMMATORY DISEASES,CYTOKINES,INFLAMMASOME,INTERLEUKIN 1,INTERLEUKIN 1 INHIBITORS, 3. Good health
Περιγραφή αρχείου: text/html
